Sabry Takes BD Reins at Roche's gRED
The recent appointment of James Sabry, MD, PhD, as Genentech's new head of business development is Roche's latest attempt to retain the spirit of the once-independent biotech icon.
You may also be interested in...
In a wide-ranging interview just four days after joining Genentech, the biotech's new head of business development outlines his team's mission, which emphasizes early-stage novel assets arising from academia and biotech.
What does Roche's privatization of Genentech mean for the companies' business development organizations and current and future partners? We recently sat down with the company's two business development chiefs to find out.
Phase I data presented at ASCO for ALLO-501 offer proof of concept for the CD19 allogeneic CAR-T and a companion drug, ALLO-647, for lymphodepletion.